Roche Sells $5.5 Billion of Bonds to Fund Telavant Buyout
- Longest portion is a 10-year note yielding 95 basis points
- Deal will also help pay dividends, potential early redemptions
Roche Holding AG headquarters in Basel, Switzerland.
Photographer: Chris Ratcliffe/BloombergThis article is for subscribers only.
Roche Holding AG sold investment-grade debt in the US corporate bond market on Monday to help fund its acquisition of Telavant Holdings Inc.
The Swiss pharmaceutical giant marketed the $5.5 billion deal in five parts, with pricing on the longest-dated portion — a 10-year note — yielding 95 basis points over the benchmark rate, after initial discussions of 115 to 120 basis points, according to a person familiar with the matter.